156 related articles for article (PubMed ID: 38242940)
1. Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy.
Jiang Y; Chen C; Liu G; Fang T; Lu N; Bei W; Dong S; Li W; Xia W; Liang H; Xiang Y
Sci Rep; 2024 Jan; 14(1):1768. PubMed ID: 38242940
[TBL] [Abstract][Full Text] [Related]
2. Is Immune Therapy Plus Chemotherapy More Effective Than Immune Therapy Alone for Unresectable Recurrent Nasopharyngeal Carcinoma?
Zhou X; Niu X; Liu P; Ou D; Zhu Y; Wang X
Front Immunol; 2021; 12():762663. PubMed ID: 34777379
[TBL] [Abstract][Full Text] [Related]
3. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis.
Luo J; Xiao W; Hua F; Cao Y; Wang D; Wang X
BMC Cancer; 2023 Nov; 23(1):1172. PubMed ID: 38037076
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial.
Zhou T; Yang Y; Ma S; Lin L; Zhou T; Zhang C; Ding X; Wang R; Feng G; Chen Y; Xu R; Huang Y; Zhang L
ESMO Open; 2021 Dec; 6(6):100313. PubMed ID: 34837744
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients.
Jiang Y; Fang T; Lu N; Bei W; Dong S; Xia W; Liang H; Xiang Y
Crit Rev Oncol Hematol; 2023 Oct; 190():104113. PubMed ID: 37633346
[TBL] [Abstract][Full Text] [Related]
7. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
Ruan X; Liang JH; Pan Y; Cai R; Zhang RJ; He Z; Yang X; Niu Z; Jiang W
Cancer; 2021 Sep; 127(17):3163-3171. PubMed ID: 34043812
[TBL] [Abstract][Full Text] [Related]
8. Preliminary evidence for endoscopic surgery combined with postoperative anti-PD-1 immunotherapy in advanced recurrent nasopharyngeal carcinoma.
Xu H; Li W; Zhang H; Wang H; Hu L; Gu Y; Wang D
BMC Cancer; 2023 Dec; 23(1):1259. PubMed ID: 38129782
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study.
Chen QY; Guo SS; Luo Y; Qu S; Wu DH; Chen XZ; Chen DP; Qin XT; Lin Q; Jin F; Lin SJ; Yao ZF; Liu W; Maxwell Wang Z; Li BY; Xia M; Xu RH; Tang LQ; Mai HQ
Oral Oncol; 2024 Apr; 151():106723. PubMed ID: 38387261
[TBL] [Abstract][Full Text] [Related]
11. Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma.
Zhang Z; Yang L; Wang D; Ruan Y; Zhang J; Zhao L; Yang L; Lou C
Ther Adv Med Oncol; 2023; 15():17588359231169981. PubMed ID: 37188111
[TBL] [Abstract][Full Text] [Related]
12. A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
Jung HA; Park KU; Cho S; Lim J; Lee KW; Hong MH; Yun T; An HJ; Park WY; Pereira S; Ock CY; Keam B
Clin Cancer Res; 2022 Oct; 28(19):4240-4247. PubMed ID: 35819451
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma.
You R; Zou X; Ding X; Zhang WJ; Zhang MX; Wang X; Xu HS; Liu YL; Ouyang YF; Duan CY; Gu CM; Wang ZQ; Liu YP; Hua YJ; Huang PY; Chen MY
Med; 2022 Oct; 3(10):664-681.e6. PubMed ID: 36041429
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the Efficacy and Safety of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma.
Sato H; Fushimi C; Okada T; Matsuki T; Kondo T; Omura GO; Miura K; Yamashita T; Okamoto I; Tsukahara K
In Vivo; 2020; 34(5):2967-2972. PubMed ID: 32871839
[TBL] [Abstract][Full Text] [Related]
15. Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.
Lee VHF; Kwong DLW; Lam KO; Lai YC; Li Y; Tong CC; Ho PPY; Chan WL; Wong LS; Leung DKC; Chan SY; Chan FT; Leung TW; Lee AWM
Medicine (Baltimore); 2017 Apr; 96(15):e6518. PubMed ID: 28403082
[TBL] [Abstract][Full Text] [Related]
16. Induction chemotherapy in nasopharyngeal carcinoma- A systematic review of phase III clinical trials.
Nazeer F; Poulose JV; Kainickal CT
Cancer Treat Res Commun; 2022; 32():100589. PubMed ID: 35724627
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
Qian X; Chen H; Tao Y
Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
[TBL] [Abstract][Full Text] [Related]
18. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in the First-Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis.
Guven DC; Stephen B; Sahin TK; Cakir IY; Aksoy S
Laryngoscope; 2024 Jan; 134(1):7-17. PubMed ID: 37227161
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review.
Adkins DR; Haddad RI
Cancer Treat Rev; 2022 Sep; 109():102428. PubMed ID: 35753157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]